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A B S T R A C T
Erdheim-Chester disease (ECD) is a rare histiocytosis usually affecting the skeletal system, but visceral organs and
central nervous system involvement are common as well. Probability exists that immunomodulatory therapies and disor-
ders can play a role in clinical course of the disease. Because of rarity of the disorder, it is hard to classify it and stan-
dardize the treatment options, but, according to published material and our experience, cytotoxic chemotherapy and
long-term steroids have therapeutic benefit. Although this approach can probably be accepted as standard of care man-
agement, novel therapeutic modalities should be explored, and pathogenesis and disorder classification should be clear-
ed out as well. The case of ECD affecting skeletal system and lungs and concomitant laryngeal tuberculosis successfully
treated with chemotherapy and long-term steroid therapy is presented.
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Case Report
A 62-year-old white male presented in April 2004 with
progressive pain in both femoral regions and right in-
guinum that started two weeks before admission to the
hospital. Initial radiological imaging and bone scinti-
graphy revealed pathologic fracture of neck of right fem-
oral bone and diaphyseal infiltrations in both femoral
bones and right humerus (Figure 1). Biopsy samples
have been taken from right femur, and revealed Erdheim-
-Chester disease (ECD), a rare form of histiocytosis. Past
medical history revealed non-insulin dependent diabetes
mellitus successfully treated with repaglinide since 2000,
when episode of acute pancreatitis occurred. Physical ex-
amination revealed mild exophtalmus and palpatory pain
in right inguinum. Computed tomography scan of the
chest, abdomen and brain revealed infiltration of left
lung parenchyma, and no other abnormalities were found
(Figure 2). Laboratory tests revealed high serum calcium
and elevated blood glucose level; no other abnormalities
were present, including hormone analysis. Pathology of
the lesion demonstrated CD1a negative, S-100 partially
positive and vimentin and CD68 positive histiocytes, all
suggestive for ECD diagnosis (Figure 3).
After implantation of partial right hip endoprothesis,
external-beam radiotherapy of right femoral region was
performed, and consequently 7 cycles of cyclophosphamide
(Endoxan) chemotherapy with concomitant PO methyl-
prednisolone (Solu-Medrol) and IV pamindronate (Aredia)
have been administered. Initial follow-up after 6 months
of chemotherapy revealed remission of the disease in the
lungs and humerus, and only right femoral bone infiltra-
tion was present. Long-term corticosteroid use was com-
plicated by worsening of diabetes mellitus and conse-
quent lipid metabolic disorder development, which are
currently controlled by insulin, methylprednisolone dose
reduction and atorvastatin (Sortis). In August 2005, pa-
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tient presented with sore throat and pain in right side of
the neck. Physical examination and radiological imaging
revealed exophytic tumor of the epiglottis. Laryngomi-
croscopy and biopsy have been performed and revealed
tuberculosis infiltration of the epiglottis and constrictor
pharyngis muscle, and one month later pulmonary tuber-
culosis developed, which has been successfully eradicated
till February 2006, by rifampicin (Rimactan), etambutol
(Etambutol), pirazynamide (Pyrazinamid) and isoniazide
(Eutizon) course. Currently, the patient is well, partici-
pating normally in daily activities, and with only detect-
able infiltration in the right femoral bone.
Discussion
ECD is a rare form of histiocytosis, first time de-
scribed as distinctive form of lipoid granulomatosis by
William Chester and Jacob Erdheim in 19301. Jaffe re-
ported a similar case in 1972, and named it Erdheim-
-Chester disease. Less than 100 cases have been de-
scribed in literature so far. ECD usually strikes the
skeletal system, but involvement of visceral organs, lungs
and central nervous system is also well recognized. De-
pending of extraskeletal involvement, it can vary from
focal indolent process to life-threatening condition. It af-
fects both sexes equally, in age range 21–77, with average
of 54 years. Bone lesions are usually sclerotic or mixed
and distributed symmetrically through the skeleton,
commonly in diaphyses and metaphyses of long bones,
but can be found in other parts of skeleton as well1,2.
Central nervous system infiltration usually can be found
in posterior lobe of pituitary gland, with consequent hy-
pothalamic-pituitary dysfunction, i.e. central diabetes
insipidus, hyperprolactinemia, gonadotropin insufficiency
and decreased insulin-like growth factor I levels. Peri-
cardial infiltration can lead to heart failure, and ret-
roperitoneal infiltration can result in renal insufficiency
with or without uretheral obstruction. Eyelid xanthomas
and exophtalmus due to retrobulbar involvement are
also common1,2. In patients with advanced lesions pulmo-
nary involvement is accompanied with pulmonary fibro-
sis, which can lead to cardiorespiratory failure3–5.
ECD has been recognized as a separate entity from
other Langerhans cell histiocytosis since its different
clinical presentation. Although it is histologically similar
to a subgroup of Langerhans cell histiocytosis, e.g. Hand-
-Schuller-Christian disease, modern immunohistochem-
istry techniques have revealed important differences be-
tween these two entities6. Several cases have been described
of patients with both diseases, as well as a case of ECD
with eosinophylic granuloma7–9. Although connection be-
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Fig. 2. Computed tomography scan of the chest, abdomen and
brain revealed infiltration of left lung parenchyma.
Fig. 3. Pathology of the lesion demonstrated CD1a negative, S-100
partially positive and vimentin and CD68 positive histiocytes, all
suggestive for ECD diagnosis.
Fig. 1. Initial radiological imaging and bone scintigraphy revealed
pathologic fracture of neck of right femoral bone and diaphyseal
infiltrations in both femoral bones and right humerus.
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tween these diseases probably exists, the pathogenesis of
ECD remains unknown. Ongoing debate persists whe-
ther it is reactive or malignant in origin, since conflicting
reports about its clonality have been published in recent
literature10,11. Having in mind common multisystem in-
volvement and poor prognosis of the disease, as well as
good efficacy of anti-cancer treatment modalities, this
rare disorder is probably neoplastic in origin, but addi-
tional clonality analyses are yet to clarify this issue.
There is no standard of care treatment for ECD. At-
tempts have been made with radiotherapy (including
half-body irradiation), chemotherapy (vincristine, vin-
blastine, doxorubicin, cyclophosphamide), immunothe-
rapy (interpheron alpha-2a)12 and corticosteroids, with
limited response. The prognosis is poor; about two thirds
of patients die of the disease, and almost 1/3 of them die
within 6 months of diagnosis11.
Further clarification of pathogenesis, standardizing
of treatment, as well as novel therapeutic approaches are
needed.
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ERDHEIM-CHESTEROVA BOLEST S PRATE]OM TUBERKULOZOM LIJE^ENA USPJE[NO
KEMOTERAPIJOM I DUGOTRAJNOM TERAPIJOM
S A @ E T A K
Erdheim-Chesterova bolest (ECD) je rijetka histiocitoza koja obi~no zahva}a ko{tani sustav, ali i unutarnje organe i
sredi{nji `iv~ani sustav. Postoji vjerojantnost da imunomodulacijske terapije i poreme}aji mogu utjecati na klini~ki tijek
bolesti. Budu}i da je bolest rijetka, te{ko ju je klasificirati i standardizirati terapiju. No, prema objavljenom materijalu i
na{em iskustvu, citotoksi~na kemoterapija i dugotrajno lije~enje steroidima imaju terapijski u~inak. Premda se ovaj
pristup mo`e prihvatiti kao standard, novi modaliteti lije~enja trebali bi biti istra`eni, a trebala bi biti razja{njena
patogeneza i klasifikacija bolesti.
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